Close Menu


Prometheus Laboratories

Some microRNA array vendors say they see no sign in market maturation, and users say there continue to be compelling reasons to add miRNA expression profiling to their research.

Papers of Note: Oct 8, 2009


RNAi-Related Papers Published September 2009

Meanwhile, the Swiss drugs and diagnostics giant is taking a measured approach to the related but nascent microRNA field, exploring partnerships with key miRNA companies and doing a certain amount of research on its own, yet keeping most of its attention focused on RNAi.

IP Update: Oct 1, 2009


USPTO Publishes Five Patents and Twelve Patent Applications Related to RNAi

Among the companies receiving funding were Isis Pharmaceuticals, Aparna Biosciences, Armagen Technologies, Omm Scientific, TekShifa, Optimum Therapeutics, and Effigene Pharmaceuticals.

The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.

Peterson and colleagues this month reported how they used the small, non-coding RNAs to resolve conflicting theories on the evolution of annelids.

IP Update: Sep 24, 2009


USPTO Published Eight Patents, Five Patent Applications Related to RNAi

Joseph DeSimone, Lin He


Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.